Skip to main content
Journal cover image

The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).

Publication ,  Journal Article
Szpak, CA; Johnston, WW; Roggli, V; Kolbeck, J; Lottich, SC; Vollmer, R; Thor, A; Schlom, J
Published in: Am J Pathol
February 1986

The correct distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung has become increasingly complex, with a variety of histochemical, immunohistochemical, and ultrastructural studies to be performed on biopsy material. The reliability of immunohistochemical studies has been hampered by the use of polyclonal antisera to "carcinoembryonic antigen (CEA)" and keratin. Hybridoma technology now offers monoclonal antibodies (MAbs) in unlimited quantity and standardized quality to selective ranges of specific antigenic determinants. MAb B72.3, generated against a membrane-enriched fraction of human metastatic breast carcinoma, was used to distinguish malignant mesothelioma of the pleura from adenocarcinoma of the lung in tissue sections and was compared in terms of diagnostic utility with polyclonal anti-keratin and anti-CEA to make the same distinction. Reactivity with MAb B72.3 in at least 10% of tumor cells or more was noted in 19 of 22 adenocarcinomas of the lung (P greater than 0.0001), whereas none of the 20 cases of malignant mesothelioma demonstrated comparable reactivity. Furthermore, MAb B72.3 showed no reactivity with benign mesothelial proliferations. MAb B72.3 thus appears to be an appropriate diagnostic adjunct capable of discriminating between these malignancies.

Duke Scholars

Published In

Am J Pathol

ISSN

0002-9440

Publication Date

February 1986

Volume

122

Issue

2

Start / End Page

252 / 260

Location

United States

Related Subject Headings

  • Pleural Neoplasms
  • Pathology
  • Mesothelioma
  • Lung Neoplasms
  • Keratins
  • Immunoenzyme Techniques
  • Humans
  • Histocytochemistry
  • Diagnosis, Differential
  • Carcinoembryonic Antigen
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Szpak, C. A., Johnston, W. W., Roggli, V., Kolbeck, J., Lottich, S. C., Vollmer, R., … Schlom, J. (1986). The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol, 122(2), 252–260.
Szpak, C. A., W. W. Johnston, V. Roggli, J. Kolbeck, S. C. Lottich, R. Vollmer, A. Thor, and J. Schlom. “The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).Am J Pathol 122, no. 2 (February 1986): 252–60.
Szpak CA, Johnston WW, Roggli V, Kolbeck J, Lottich SC, Vollmer R, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol. 1986 Feb;122(2):252–60.
Szpak CA, Johnston WW, Roggli V, Kolbeck J, Lottich SC, Vollmer R, Thor A, Schlom J. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J Pathol. 1986 Feb;122(2):252–260.
Journal cover image

Published In

Am J Pathol

ISSN

0002-9440

Publication Date

February 1986

Volume

122

Issue

2

Start / End Page

252 / 260

Location

United States

Related Subject Headings

  • Pleural Neoplasms
  • Pathology
  • Mesothelioma
  • Lung Neoplasms
  • Keratins
  • Immunoenzyme Techniques
  • Humans
  • Histocytochemistry
  • Diagnosis, Differential
  • Carcinoembryonic Antigen